The global cholesterol test market size was valued at USD 8.85 billion in 2025 and is projected to grow from USD 9.50 billion in 2026 to USD 16.83 billion by 2034, registering a CAGR of 7.4% during the forecast period from 2026 to 2034. North America dominated the cholesterol test market with a market share of 38.6% in 2025.
A cholesterol test, also known as a lipid panel or lipid profile, is a blood test used to measure cholesterol levels and other fats in the bloodstream. It evaluates total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. This test is crucial for assessing the risk of cardiovascular diseases such as heart attacks and strokes.
Download a Free Sample To learn more about this report,
Growing Adoption of Advanced Lipid and Lipoprotein Biomarker Testing
Cholesterol testing is moving beyond conventional measurements of total cholesterol, LDL-C, HDL-C, and triglycerides toward more detailed lipid and lipoprotein assessment. Advanced biomarkers such as Lipoprotein(a) [Lp(a)] and Apolipoprotein B (ApoB) can provide additional information about cardiovascular risk that may not be fully captured through a standard lipid profile. This transition is encouraging diagnostic laboratories and cardiovascular care providers to broaden testing portfolios and incorporate additional biomarkers into individualized risk assessment.
The increasing clinical recognition of additional lipid biomarkers is shifting cholesterol testing toward more comprehensive cardiovascular risk profiling and supporting the adoption of tests that complement conventional cholesterol measurements.
Increasing Use of Lipidomics for Detailed Cardiovascular Risk Assessment
Lipidomics is emerging as an advanced approach for examining numerous lipid species rather than relying exclusively on conventional cholesterol measurements. Mass-spectrometry-based techniques can characterize ceramides, phospholipids, lysophospholipids, and other lipid molecules associated with cardiovascular disease. This approach provides researchers with a more detailed understanding of lipid metabolism and may help identify biomarkers associated with disease development and progression.
As lipidomics technologies become more standardized and clinically validated, they could complement conventional cholesterol testing and support more precise cardiovascular risk assessment.
High Burden of Elevated Cholesterol Increases Routine Testing Requirements
The high prevalence of abnormal cholesterol levels is strengthening cholesterol test market demand because elevated LDL cholesterol is an established risk factor for atherosclerotic cardiovascular disease. Excess LDL-C can contribute to plaque accumulation in arteries, increasing the long-term risk of heart attack and stroke. Since high cholesterol generally produces no obvious symptoms, laboratory testing remains important for identifying individuals requiring preventive intervention and ongoing lipid management.
The continuing burden of elevated cholesterol is supporting routine testing across primary care practices, hospitals, diagnostic laboratories, preventive healthcare programs, and cardiovascular clinics.
Cost and Infrastructure Requirements of Advanced Lipid Testing
Advanced cholesterol and lipid assessment can require specialized analyzers, mass spectrometry platforms, reagents, skilled laboratory personnel, and sophisticated data-processing capabilities. These requirements make advanced lipidomic and specialized biomarker testing more complex and expensive than conventional lipid panels available through routine clinical chemistry laboratories.
Such infrastructure requirements can restrict the cholesterol test market size, particularly across smaller laboratories, community healthcare facilities, and developing healthcare systems where sophisticated diagnostic technologies are less accessible.
Reducing analytical complexity, improving assay standardization, and lowering testing costs will be important for extending advanced lipid assessment beyond specialized laboratories and cardiovascular centers.
Expansion of Lp(a) and ApoB Testing Creates New Diagnostic Opportunities
Increasing recognition of cardiovascular risk beyond conventional LDL-C measurements is creating opportunities for diagnostic companies and laboratories offering specialized lipid assays. Lp(a) is largely genetically determined, while ApoB provides information about atherogenic lipoprotein particles. These biomarkers can provide additional cardiovascular risk information when conventional cholesterol results alone are insufficient.
Companies expanding access to standardized Lp(a), ApoB, and related assays have opportunities to strengthen their cholesterol test market share as cardiovascular prevention becomes increasingly personalized.
Broader incorporation of these biomarkers into cardiovascular assessment creates opportunities for assay manufacturers, diagnostic laboratories, and testing platforms to expand beyond conventional lipid panels.
Limited Preventive Screening Leaves Lipid Disorders Undiagnosed
Ensuring that eligible populations undergo routine lipid screening remains an important challenge for the cholesterol test industry. Elevated cholesterol generally does not produce noticeable symptoms, meaning individuals can remain unaware of abnormal lipid levels for years. Limited awareness, inadequate primary healthcare access, diagnostic infrastructure gaps, and inconsistent preventive screening can further delay identification.
The problem is particularly relevant among younger populations, where cholesterol testing may receive less attention despite the importance of detecting familial hypercholesterolemia and other inherited lipid disorders early.
Improving awareness, preventive healthcare participation, and access to routine lipid testing remains important for reducing undiagnosed lipid disorders and supporting earlier cardiovascular intervention.
Testing Kits Dominated the Market with 48.3% Share in 2025
Testing kits accounted for the largest share of the global cholesterol test market at 48.3% in 2025, valued at USD 4.27 billion. The segment's dominance is attributed to the widespread adoption of rapid diagnostic kits, increasing preventive health screening, and growing demand for convenient point-of-care and home-based cholesterol testing solutions.
Request Customizationto receive a tailored report.
Total Cholesterol Tests Held the Largest Market Share at 31.7% in 2025
The total cholesterol tests segment held the largest market share of 31.7% in 2025, reaching USD 2.81 billion. The segment continues to lead due to its routine use in cardiovascular risk assessment, annual health check-ups, and preventive screening programs across hospitals and diagnostic laboratories.
Diabetes is Projected to Register the Fastest Growth at a CAGR of 8.8%
The diabetes segment is expected to witness the fastest growth, registering a CAGR of 8.8% during 2026–2034. Rising diabetes prevalence, increased risk of dyslipidemia among diabetic patients, and the growing emphasis on routine lipid monitoring are driving demand for cholesterol testing in diabetes management.
Hospitals and Clinics Dominated the Market with 41.5% Share in 2025
Hospitals and clinics accounted for the largest share of the global cholesterol test market at 41.5% in 2025, valued at USD 3.67 billion. The segment is driven by high patient volumes, comprehensive cardiovascular screening services, and the availability of advanced diagnostic infrastructure for lipid profile testing.
Speak to an Analystto discuss market opportunities.
North America dominated the global cholesterol test market with a 38.6% market share, valued at USD 3.42 billion in 2025. The region benefits from a high prevalence of cardiovascular diseases, widespread preventive health screening programs, advanced diagnostic infrastructure, and strong awareness of lipid monitoring. Favorable reimbursement policies and increasing adoption of point-of-care cholesterol testing continue to support market growth.
The United States accounted for an estimated USD 2.94 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by rising cardiovascular disease prevalence, routine cholesterol screening initiatives, increasing adoption of home-based lipid testing, and the presence of leading diagnostic manufacturers and clinical laboratory networks.
Canada generated an estimated USD 0.48 billion in 2025. Growing government support for preventive healthcare, increasing awareness of cardiovascular risk management, and expanding access to diagnostic services are driving demand for cholesterol testing across hospitals, clinics, and diagnostic laboratories.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific accounted for 23.1% of the global market, valued at USD 2.04 billion in 2025, and is projected to register the fastest CAGR of 9.8% during the forecast period. Rapid urbanization, rising healthcare expenditure, increasing incidence of obesity and cardiovascular diseases, and expanding diagnostic infrastructure are accelerating market growth across the region.
Japan generated an estimated USD 0.47 billion in 2025. The country's aging population, high prevalence of lifestyle-related diseases, regular health check-up culture, and strong adoption of advanced diagnostic technologies continue to drive demand for cholesterol testing.
China accounted for an estimated USD 0.95 billion in 2025, making it the largest market in Asia Pacific. Government healthcare reforms, expanding hospital infrastructure, growing health awareness, and increasing investments in preventive healthcare are supporting strong market growth.
Europe accounted for 27.2% of the global cholesterol test market share, reaching USD 2.41 billion in 2025. The market is supported by well-established healthcare systems, increasing cardiovascular disease screening programs, growing emphasis on preventive healthcare, and rising adoption of advanced laboratory diagnostic technologies.
The United Kingdom represented an estimated USD 0.42 billion in 2025. The country's market is driven by NHS preventive screening initiatives, increasing public awareness of heart health, and growing demand for early lipid profile testing to reduce cardiovascular disease burden.
Germany generated an estimated USD 0.56 billion in 2025, making it one of the leading contributors in Europe. The country's advanced healthcare infrastructure, high healthcare expenditure, increasing laboratory automation, and strong focus on preventive diagnostics continue to support market expansion.
The Middle East & Africa represented 4.7% of the global cholesterol test market, totaling USD 0.42 billion in 2025. Rising investments in healthcare infrastructure, increasing awareness of cardiovascular disease prevention, expanding diagnostic laboratory networks, and improving access to preventive screening services are supporting regional market growth.
The United Arab Emirates (UAE) accounted for an estimated USD 0.12 billion in 2025. The market is driven by government investments in healthcare modernization, increasing prevalence of lifestyle-related disorders, growing adoption of preventive health check-ups, and expansion of advanced diagnostic facilities.
Latin America accounted for 6.4% of the global cholesterol test market, reaching USD 0.57 billion in 2025. Rising awareness of cardiovascular health, improving healthcare access, increasing chronic disease prevalence, and expanding diagnostic laboratory services are contributing to steady regional market growth.
Brazil generated an estimated USD 0.24 billion in 2025, making it the largest market in Latin America. Increasing government initiatives for non-communicable disease prevention, expanding private diagnostic laboratory networks, and rising adoption of routine cholesterol screening continue to strengthen market growth.
The global cholesterol test industry is moderately fragmented in nature due to the presence of established diagnostic companies, clinical laboratories, and specialized testing providers competing across testing kits, testing strips, point-of-care systems, and laboratory-based lipid testing. The top players in the industry are Thermo Fisher Scientific Inc., Elabscience Bionovation Inc., Quest Diagnostics Incorporated, Cell Biolabs Inc., Spectra Laboratories Inc., BioReference Health LLC, Clinical Reference Laboratory Inc., Labcorp, Randox Laboratories Ltd., Eurofins Scientific, SYNLAB AG, Verichem Laboratories Inc., Merck KGaA, Abbott, and others.
The industry participants are inclined towards product innovation to improve testing accuracy, speed, accessibility, and convenience. Companies are increasingly focusing on point-of-care analyzers, finger-prick testing, home-based kits, automated lipid profiling, and integrated diagnostic services that measure total cholesterol, LDL, HDL, triglycerides, and other cardiovascular risk markers. Preventive healthcare and decentralized testing are also encouraging wider adoption of rapid cholesterol screening technologies.
Abbott has a strong presence in point-of-care diagnostics and provides cholesterol and lipid testing technologies for rapid cardiovascular risk assessment. Its diagnostic capabilities support testing in physician offices, hospitals, health screening programs, and other decentralized healthcare environments.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
qPCR Instruments Market Size, Share, Growth, Forecast, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
Serum-Free Media Market Size, Share, Growth, Forecast, 2034
Preimplantation Genetic Testing Market Size, Share, Growth, 2034
Single-Cell Multi-Omics Market Size, Share, Growth, 2034
Molecular Diagnostics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com